Inflammatory disease Archives

gsk morphosys hand osteoarthritis rheumatoid

News and Trends 19 Apr 2016

GSK goes to phase II with German Antibody for Inflammatory Diseases

GSK has started a phase II trial for inflammatory hand osteoarthritis, with a candidate originally from MorphoSys‘ antibody library. GSK, a big UK Pharma, has announced the start of a phase II study to evaluate the efficacy and safety of its candidate, GSK3196165. The trial will enroll 40 patients with hand osteoarthritis – a condition that damages […]

April 19, 2016 - 2 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

samsung bioepis biotech rheumatoid arthritis biosimilar flixabi sb4

News and Trends 5 Apr 2016

Samsung’s Rheumatoid Biosimilar could now make it to the EU Market

Samsung Bioepis (South Korea) has gotten an approval recommendation from the EMA for one of its 13 in-development biosimilars: Flixabi, a biosimilar of Janssen’s blockbuster Remicade for Inflammatory diseases. Samsung Bioepis is a joint venture between Biogen and Samsung BioLogics, a branch of the Korean giant that provides manufacturing services for development of biologicals. It started developing […]

April 5, 2016 - 3 minutesmins - By Denise Neves Gameiro

capella biosciences medicxi ventures advent life sciences osage university partners mabs monoclonal antibodies oncology autoimmune target biology

News and Trends 10 Mar 2016

Antibody Start-up Gets a Slice of a Rebranded €210M Life Sciences Fund

Capella Biosciences (UK) is a life sciences start-up specializing in antibodies. It has just raised an additional €14.3M in a Series A round to develop their antibody pipeline to clinical stages. Capella started out in 2014 and based in London, defining its mission as developing therapeutic monoclonal antibodies for unmet medical needs. Back then, it received […]

March 10, 2016 - 2 minutesmins - By Denise Neves Gameiro

boehringer ingelheim abbvie psoriasis interleukin23 bi655066 bi655066 Crohns asthma psoriatic arthritis

News and Trends 9 Mar 2016

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Boehringer Ingelheim (Germany) has entered a new collaboration with AbbVie (US) to develop two new candidates for immune diseases, including psoriasis and Crohn’s disease. Therapies for immune diseases continue to attract Pharma’s attention (and money). This time, two of 25 leading Big Pharma worldwide, AbbVie and Boehringer Ingelheim, have partnered to develop 2 different immunological candidates. […]

March 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

redhill biopharma israel gastrointestinal crohns cancer pancreatic rhb 104

News and Trends 3 Mar 2016

This Leading Israeli Biopharma is in Good Shape to fight Crohn’s Disease

RedHill Biopharma (Israel) is in a solid financial position to reap the benefits of several advanced trials in inflammatory gastrointestinal diseases, including Crohn’s. The company just released its financial statements, with some interesting highlights… Based in Tel-Aviv, RedHill is developing small molecule oral drugs for a variety of conditions connected to the gastrointestinal tract. It is listed […]

March 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

enterome pierre belichard microbiome crohns ibd

News and Trends 3 Feb 2016

Meet the CEO of Europe’s Leading Microbiome Biotech

We met Pierre Belichard, the CEO of Enterome, last week to discuss the increasingly famous trend in the Human Microbiome and how this is impacting therapeutics in Crohn’s disease, the understanding of Medical Microbiomics and investment in this field of Biotech. Enterome, established in 2012, is a French biotech that is hot at the moment, […]

February 3, 2016 - 5 minutesmins - By Philip Hemme

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

embl microbiome janssen eligo enterome jj inra therapeutics crohns

News and Trends 7 Jan 2016

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda are signing up to collaborate with the Paris biotech Enterome to help accelerate Microbiomics research into Crohn’s Disease. The collaboration is based on initial findings by the INRA showing that some commensal (symbiotic) bacteria elicit […]

January 7, 2016 - 3 minutesmins - By Dani Bancroft

Gilead galapagos abbvie filgotinib partner rheumatoid

News and Trends 18 Dec 2015

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie‘s shocking abandonment. The Mystery replacement partner has now been revealed as Gilead! Galapagos will receive an upfront payment of €670M from California’s Gilead, consisting of a license fee of €277M and a €393M equity investment in Galapagos. In addition, […]

December 18, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us